177 related articles for article (PubMed ID: 6541243)
1. Activation of peritoneal lymphocyte cytotoxicity in patients with ovarian cancer by intraperitoneal treatment with Corynebacterium parvum.
Lichtenstein A; Berek J; Bast R; Spina C; Hacker N; Knapp RC; Zighelboim J
J Biol Response Mod; 1984 Aug; 3(4):371-8. PubMed ID: 6541243
[TBL] [Abstract][Full Text] [Related]
2. Natural killer inhibitory substance produced by the peritoneal cells of patients with ovarian cancer.
Lichtenstein AK; Berek J; Zighelboim J
J Natl Cancer Inst; 1985 Feb; 74(2):349-55. PubMed ID: 3856049
[TBL] [Abstract][Full Text] [Related]
3. Lymphocyte cytotoxicity in the peritoneal cavity and blood of patients with ovarian cancer.
Berek JS; Bast RC; Lichtenstein A; Hacker NF; Spina CA; Lagasse LD; Knapp RC; Zighelboim J
Obstet Gynecol; 1984 Nov; 64(5):708-14. PubMed ID: 6493663
[TBL] [Abstract][Full Text] [Related]
4. Role of inflammatory neutrophils in antitumor effects induced by intraperitoneal administration of Corynebacterium parvum in mice.
Lichtenstein AK; Berek J; Kahle J; Zighelboim J
Cancer Res; 1984 Nov; 44(11):5118-23. PubMed ID: 6488171
[TBL] [Abstract][Full Text] [Related]
5. Intraperitoneal immunotherapy of human ovarian carcinoma with Corynebacterium parvum.
Bast RC; Berek JS; Obrist R; Griffiths CT; Berkowitz RS; Hacker NF; Parker L; Lagasse LD; Knapp RC
Cancer Res; 1983 Mar; 43(3):1395-401. PubMed ID: 6825108
[TBL] [Abstract][Full Text] [Related]
6. IL-2 enhances standard IFNgamma/LPS activation of macrophage cytotoxicity to human ovarian carcinoma in vitro: a potential for adoptive cellular immunotherapy.
Han X; Wilbanks GD; Devaja O; Ruperelia V; Raju KS
Gynecol Oncol; 1999 Nov; 75(2):198-210. PubMed ID: 10525372
[TBL] [Abstract][Full Text] [Related]
7. Immunologic control of a retrovirus-associated murine adenocarcinoma. VIII. Corynebacterium parvum-activated natural killer cells as potent antibody-dependent cell-mediated cytotoxicity effectors.
Weinhold KJ; Bolognesi DP; Matthews TJ
J Natl Cancer Inst; 1985 Oct; 75(4):717-24. PubMed ID: 3862904
[TBL] [Abstract][Full Text] [Related]
8. Intraperitoneal recombinant alpha-interferon for "salvage" immunotherapy in stage III epithelial ovarian cancer: a Gynecologic Oncology Group Study.
Berek JS; Hacker NF; Lichtenstein A; Jung T; Spina C; Knox RM; Brady J; Greene T; Ettinger LM; Lagasse LD
Cancer Res; 1985 Sep; 45(9):4447-53. PubMed ID: 4028027
[TBL] [Abstract][Full Text] [Related]
9. Immunotherapy of a murine ovarian carcinoma with Corynebacterium parvum and specific heteroantiserum. I. Activation of peritoneal cells to mediate antibody-dependent cytotoxicity.
Bast RC; Knapp RC; Mitchell AK; Thurston JG; Tucker RW; Schlossman SF
J Immunol; 1979 Nov; 123(5):1945-51. PubMed ID: 489967
[TBL] [Abstract][Full Text] [Related]
10. Successful immunotherapy with intraperitoneal Corynebacterium parvum in a murine ovarian cancer model is associated with the recruitment of tumor-lytic neutrophils into the peritoneal cavity.
Lichtenstein AK; Kahle J; Berek J; Zighelboim J
J Immunol; 1984 Jul; 133(1):519-26. PubMed ID: 6373934
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of experimental tumor metastasis by selective activation of natural killer cells.
Hanna N
Cancer Res; 1982 Apr; 42(4):1337-42. PubMed ID: 6277482
[TBL] [Abstract][Full Text] [Related]
12. Intraperitoneal recombinant alpha 2-interferon for 'salvage' immunotherapy in persistent epithelial ovarian cancer.
Berek JS; Hacker NF; Lichtenstein A; Jung T; Spina C; Knox RM; Brady J; Greene T; Ettinger LM; Lagasse LD
Cancer Treat Rev; 1985 Dec; 12 Suppl B():23-32. PubMed ID: 3833327
[TBL] [Abstract][Full Text] [Related]
13. Regulation of natural killer cell activation: implementation for the control of tumor metastasis.
Hanna N
Nat Immun Cell Growth Regul; 1983-1984; 3(1):22-33. PubMed ID: 6235447
[TBL] [Abstract][Full Text] [Related]
14. Murine lymph node natural killer cells: regulatory mechanisms of activation or suppression.
Hisano G; Hanna N
J Natl Cancer Inst; 1982 Sep; 69(3):665-71. PubMed ID: 6180211
[TBL] [Abstract][Full Text] [Related]
15. Attempts to correlate interferon induction and activation of natural killer cells by Corynebacterium parvum.
Chmielarczyk W; Kirchner H; Ernst R; Storch E
Immunobiology; 1985 May; 169(4):403-11. PubMed ID: 2408996
[TBL] [Abstract][Full Text] [Related]
16. Alteration in natural defense activity against NK-susceptible B16 melanoma cells after treatment with Corynebacterium parvum.
Karashima A; Taniguchi K; Yoshikai Y; Nomoto K
Immunobiology; 1991 Aug; 182(5):414-24. PubMed ID: 1916884
[TBL] [Abstract][Full Text] [Related]
17. Effect of pregnancy on augmentation of natural killer cell activity by Corynebacterium parvum and Toxoplasma gondii.
Luft BJ; Remington JS
J Immunol; 1984 May; 132(5):2375-80. PubMed ID: 6715884
[TBL] [Abstract][Full Text] [Related]
18. Intraperitoneal administration of human recombinant interferon-alpha in patients with ovarian cancer: effects on lymphocyte phenotype and cytotoxicity.
Lichtenstein A; Spina C; Berek JS; Jung T; Zighelboim J
Cancer Res; 1988 Oct; 48(20):5853-9. PubMed ID: 3167841
[TBL] [Abstract][Full Text] [Related]
19. Immunologic control of ovarian cancer.
Zighelboim J; Nio Y; Berek JS; Bonavida B
Nat Immun Cell Growth Regul; 1988; 7(4):216-25. PubMed ID: 3070371
[No Abstract] [Full Text] [Related]
20. Local immunotherapy with interferon-alpha in metastatic pleural and peritoneal effusions: correlation with immunologic parameters.
Stathopoulos GP; Baxevanis CN; Papadopoulos NG; Zarkadis IK; Papacostas P; Michailakis E; Tsiatas ML; Papamichail M
Anticancer Res; 1996; 16(6B):3855-60. PubMed ID: 9042270
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
